Human tissue factor antibodies
OwnerPer-Ola Freskgaard, Jes Clausen Clausen +2inventors
InventorsPer-Ola Freskgaard, Jes Clausen Clausen, Brit Binow Sorensen, Marianne Kjalke
Life of this patent
Estimating the term…
Abstract
The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa).
Claims49
An isolated human antibody, wherein said antibody immunoreacts with an epitope present on human tissue factor (TF).
A pharmaceutical composition comprising a therapeutically effective amount of a human antibody, wherein said antibody immunoreacts with an epitope present on human TF.
A composition comprising a human antibody, which immunoreacts with an epitope present on human TF.
A method for treatment of a FVIIa/TF related disorder in a human, which method comprises administering to said human a therapeutically effective amount of a human antibody, wherein said antibody immunoreacts with an epitope present on human TF.
A method for preparation of a human antibody, said method comprising:
- a) Preparing human antibodies against human TF,
- b) Testing said antibodies in (i) a TF-induced clot assay and selecting human antibody which inhibit clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, or (ii) a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa), or (iii) a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa in the assay), or (iv) a FVIIa competition assay and selecting human antibody which compete with FVIIa binding, (v) a TF ELISA assay comprising TF and selecting human antibody which immunoreacts with human TF.
A human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF, wherein said antibody is obtainable by a method comprising:
- a) Preparation of human antibodies against human TF,
- b) testing antibodies in a TF-induced clot assay and selecting human antibody which inhibit clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa, or testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM, preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa, or
- testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa, or
- testing antibodies in a FVIIa competition assay and selecting human antibody which compete with FVIIa binding, or
- testing antibodies in a TF ELISA assay comprising TF and selecting human antibody which immunoreacts with human TF.
A method for preparation of a human antibody, which method comprises
- a) immunizing a mouse with human TF,
- b) isolating antibody-producing cell from said immunized mouse and preparing of immortal cells that secrete human antibodies,
- c) isolating culture medium from said immortal cells, wherein said culture medium comprises produced antibodies,
- d) testing said antibodies in an indirect TF ELISA assay comprising TF in solution and selecting human antibodies that immunoreact with human TF in solution,
- e) testing said antibodies in a FVIIa competition assay and selecting human antibodies which competes with FVIIa binding,
- f) testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nm FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
- g) testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
- h) testing antibodies in a TF-induced clot assay and selecting human antibodies which inhibits clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa,
- i) selection and cultivation in a suitable culture medium of the immortal cell producing the selected antibody following step d-h,
- j) isolation of selected antibody from culture medium of selected immortal cell.
A human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF obtainable by a method comprising:
- a) immunization of mouse with human TF,
- b) isolation of antibody-producing cell from immunized mouse and preparation of immortal cells to secrete human antibodies,
- c) isolation of culture medium from immortal cells comprising produced antibodies,
- d) testing antibodies in an indirect TF ELISA assay comprising TF in solution and selecting human antibodies which immunoreacts with human TF in solution,
- e) testing antibodies in a FVIIa competition assay and selecting human antibodies which competes with FVIIa binding,
- f) testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
- g) testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM, preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
- h) testing antibodies in a TF-induced clot assay and selecting human antibodies which inhibits clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa,
- i) selection and cultivation in a suitable culture medium of the immortal cell producing the selected antibody following step d-h,
- j) isolation of selected antibody from culture medium of selected immortal cell.
A cell producing human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF.
Dependencies are inferred from the claim text.